Paul Badawi Sells 24,819 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CEO Paul Badawi sold 24,819 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $2.92, for a total value of $72,471.48. Following the transaction, the chief executive officer now owns 5,676,331 shares of the company’s stock, valued at $16,574,886.52. This trade represents a 0.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Paul Badawi also recently made the following trade(s):

• On Thursday, January 2nd, Paul Badawi sold 12,236 shares of Sight Sciences stock. The stock was sold at an average price of $3.60, for a total transaction of $44,049.60.

Sight Sciences Stock Performance

NASDAQ:SGHT opened at $2.96 on Friday. The firm has a market capitalization of $150.23 million, a PE ratio of -2.90 and a beta of 2.57. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The business’s fifty day moving average price is $3.55 and its 200 day moving average price is $5.32. Sight Sciences, Inc. has a 12 month low of $2.67 and a 12 month high of $8.45.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. The business had revenue of $20.16 million for the quarter, compared to analyst estimates of $20.41 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. On average, sell-side analysts anticipate that Sight Sciences, Inc. will post -1.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Lake Street Capital reduced their target price on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Wednesday, January 15th. Piper Sandler reiterated a “neutral” rating and issued a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a research note on Friday, November 8th. UBS Group began coverage on Sight Sciences in a research note on Friday, December 6th. They set a “buy” rating and a $5.50 target price for the company. Morgan Stanley reduced their price target on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, November 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research report on Tuesday, January 14th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.72.

Institutional Trading of Sight Sciences

Several institutional investors have recently modified their holdings of SGHT. KCK LTD. purchased a new position in shares of Sight Sciences in the 4th quarter valued at $15,925,000. Geode Capital Management LLC grew its holdings in shares of Sight Sciences by 1.6% during the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares during the last quarter. State Street Corp increased its position in shares of Sight Sciences by 17.4% during the third quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after purchasing an additional 95,843 shares in the last quarter. Long Focus Capital Management LLC lifted its holdings in shares of Sight Sciences by 86.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock valued at $3,739,000 after purchasing an additional 260,594 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of Sight Sciences by 46.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 207,893 shares of the company’s stock valued at $1,310,000 after purchasing an additional 65,767 shares during the period. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.